CO6940429A2 - Compuestos heterocíclicos, medicamentos que los contienen, uso de aquellos y procesos para su preparación - Google Patents

Compuestos heterocíclicos, medicamentos que los contienen, uso de aquellos y procesos para su preparación

Info

Publication number
CO6940429A2
CO6940429A2 CO14092699A CO14092699A CO6940429A2 CO 6940429 A2 CO6940429 A2 CO 6940429A2 CO 14092699 A CO14092699 A CO 14092699A CO 14092699 A CO14092699 A CO 14092699A CO 6940429 A2 CO6940429 A2 CO 6940429A2
Authority
CO
Colombia
Prior art keywords
medicines
contain
processes
preparation
those
Prior art date
Application number
CO14092699A
Other languages
English (en)
Spanish (es)
Inventor
Armin Heckel
Sara Frattini
Dieter Hamprecht
Joerg Kley
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CO6940429A2 publication Critical patent/CO6940429A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
CO14092699A 2011-11-02 2014-04-30 Compuestos heterocíclicos, medicamentos que los contienen, uso de aquellos y procesos para su preparación CO6940429A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11187553 2011-11-02

Publications (1)

Publication Number Publication Date
CO6940429A2 true CO6940429A2 (es) 2014-05-09

Family

ID=47073464

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14092699A CO6940429A2 (es) 2011-11-02 2014-04-30 Compuestos heterocíclicos, medicamentos que los contienen, uso de aquellos y procesos para su preparación

Country Status (34)

Country Link
US (4) US8759349B2 (cg-RX-API-DMAC7.html)
EP (1) EP2773633B1 (cg-RX-API-DMAC7.html)
JP (1) JP6091513B2 (cg-RX-API-DMAC7.html)
KR (1) KR102006612B1 (cg-RX-API-DMAC7.html)
CN (2) CN106279110B (cg-RX-API-DMAC7.html)
AP (1) AP2014007670A0 (cg-RX-API-DMAC7.html)
AU (1) AU2012331274B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014010583A2 (cg-RX-API-DMAC7.html)
CA (1) CA2854217C (cg-RX-API-DMAC7.html)
CL (1) CL2014001047A1 (cg-RX-API-DMAC7.html)
CO (1) CO6940429A2 (cg-RX-API-DMAC7.html)
CY (1) CY1120974T1 (cg-RX-API-DMAC7.html)
DK (1) DK2773633T3 (cg-RX-API-DMAC7.html)
EA (1) EA025158B9 (cg-RX-API-DMAC7.html)
EC (1) ECSP14001929A (cg-RX-API-DMAC7.html)
ES (1) ES2645744T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20186880B (cg-RX-API-DMAC7.html)
HR (1) HRP20171614T1 (cg-RX-API-DMAC7.html)
HU (1) HUE034929T2 (cg-RX-API-DMAC7.html)
IL (1) IL232035A (cg-RX-API-DMAC7.html)
LT (1) LT2773633T (cg-RX-API-DMAC7.html)
ME (1) ME02905B (cg-RX-API-DMAC7.html)
MX (1) MX348522B (cg-RX-API-DMAC7.html)
NO (1) NO2773633T3 (cg-RX-API-DMAC7.html)
PE (1) PE20141607A1 (cg-RX-API-DMAC7.html)
PH (1) PH12014500970B1 (cg-RX-API-DMAC7.html)
PL (1) PL2773633T3 (cg-RX-API-DMAC7.html)
PT (1) PT2773633T (cg-RX-API-DMAC7.html)
RS (1) RS56498B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201401907TA (cg-RX-API-DMAC7.html)
SI (1) SI2773633T1 (cg-RX-API-DMAC7.html)
TN (1) TN2014000180A1 (cg-RX-API-DMAC7.html)
UA (1) UA115868C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013064450A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE032813T2 (en) 2005-12-28 2017-11-28 Vertex Pharma Solid forms of N- [2,4-bis (1,1-dimethyl ethyl) -5-hydroxyphenyl] -1,4-dihydro-4-oxoquinoline-3-carboxamide
PL2773633T3 (pl) * 2011-11-02 2018-01-31 Boehringer Ingelheim Int Związki heterocykliczne, leki zawierające wymienione związki, ich zastosowanie i procesy ich wytwarzania
KR20160054460A (ko) * 2013-07-02 2016-05-16 더 캘리포니아 인스티튜트 포 바이오메디칼 리써치 낭성 섬유증의 치료를 위한 화합물
WO2015003958A1 (en) * 2013-07-08 2015-01-15 Boehringer Ingelheim International Gmbh Amiloride-type compounds as inhibitors in epithelial sodium channels for the treatment of diseases of the lungs and airways
EP3204358B1 (en) 2014-10-07 2018-09-19 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
SG11201703284XA (en) 2014-10-24 2017-06-29 Ono Pharmaceutical Co Kcnq2-5 channel activator
HK1246718A1 (zh) * 2015-01-07 2018-09-14 斯克利普斯研究所 用於治疗囊性纤维化的化合物
GB201610854D0 (en) 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds
GB201717051D0 (en) 2017-10-17 2017-11-29 Enterprise Therapeutics Ltd Compounds
GB201808093D0 (en) 2018-05-18 2018-07-04 Enterprise Therapeutics Ltd Compounds
AU2021341508A1 (en) 2020-09-10 2023-05-25 Precirix N.V. Antibody fragment against fap
CN112107580A (zh) * 2020-09-29 2020-12-22 北京鑫开元医药科技有限公司 一种脾酪氨酸激酶抑制剂的制剂组合物及其制备方法
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
IL318992A (en) 2022-05-02 2025-04-01 Precirix N V Cancer treatment through advance directives
WO2024243025A1 (en) * 2023-05-19 2024-11-28 Ikena Oncology, Inc. Naphthyl-substituted pyrido[4,3-d]pyrimidines and related compounds and their use in treating medical conditions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6812003A (cg-RX-API-DMAC7.html) 1967-09-07 1969-03-11
US3953476A (en) 1971-12-27 1976-04-27 Merck & Co., Inc. 3-Amino-5-sulfonylbenzoic acids
AU774865B2 (en) 1999-07-19 2004-07-08 University Of North Carolina At Chapel Hill, The Conjugates of sodium channel blockers and methods of using the same
WO2001052902A1 (en) 2000-01-24 2001-07-26 Isis Pharmaceuticals, Inc. Antisense modulation of inducible nitric oxide synthase expression
WO2006023573A2 (en) 2004-08-18 2006-03-02 Johnson Michael R Aliphatic amide & ester pyrazinoylguanidine sodium channel blockers
GB0526244D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
WO2008013557A1 (en) * 2006-07-24 2008-01-31 International Stem Cell Corporation Synthetic cornea from retinal stem cells
ATE499363T1 (de) * 2007-05-07 2011-03-15 Novartis Ag Organische verbindungen
NZ585789A (en) 2007-12-10 2012-03-30 Novartis Ag Pyrazine-2-carboxamide derivatives to treat diseases mediated by blockade of the epithelial sodium channel
EP2285785B1 (en) * 2008-05-13 2012-09-05 Novartis AG 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid derivatives and their use as epithelial sodium channel blockers for the treatment of arway diseases
MX2010013675A (es) 2008-06-10 2011-02-15 Novartis Ag Derivados de pirazina como bloqueadores del canal de sodio epitelial.
US9050339B2 (en) 2010-09-17 2015-06-09 Novartis Ag Pyrazine derivatives as ENaC blockers
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
CA2839709C (en) 2011-06-27 2020-01-14 Parion Sciences, Inc. A chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity
CN104024231A (zh) 2011-11-02 2014-09-03 勃林格殷格翰国际有限公司 制备酰基胍和酰基硫脲化合物的新方法
PL2773633T3 (pl) * 2011-11-02 2018-01-31 Boehringer Ingelheim Int Związki heterocykliczne, leki zawierające wymienione związki, ich zastosowanie i procesy ich wytwarzania

Also Published As

Publication number Publication date
IL232035A0 (en) 2014-05-28
EA025158B9 (ru) 2018-03-30
MX2014005166A (es) 2014-05-28
HUE034929T2 (en) 2018-03-28
KR20140085498A (ko) 2014-07-07
JP2014534222A (ja) 2014-12-18
PH12014500970B1 (en) 2017-10-06
CA2854217A1 (en) 2013-05-10
AP2014007670A0 (en) 2014-05-31
US20180194747A1 (en) 2018-07-12
SG11201401907TA (en) 2014-05-29
JP6091513B2 (ja) 2017-03-08
GEP20186880B (en) 2018-07-25
DK2773633T3 (da) 2017-11-13
US20150336933A1 (en) 2015-11-26
EP2773633A1 (en) 2014-09-10
ME02905B (me) 2018-10-20
PT2773633T (pt) 2017-11-14
KR102006612B1 (ko) 2019-08-02
UA115868C2 (uk) 2018-01-10
PH12014500970A1 (en) 2014-06-09
MX348522B (es) 2017-06-16
SI2773633T1 (sl) 2017-11-30
RS56498B1 (sr) 2018-01-31
TN2014000180A1 (en) 2015-09-30
ECSP14001929A (es) 2015-11-30
AU2012331274A1 (en) 2014-04-03
IL232035A (en) 2017-05-29
EP2773633B1 (en) 2017-08-02
US20130109697A1 (en) 2013-05-02
BR112014010583A2 (pt) 2020-04-22
NZ622469A (en) 2016-08-26
PL2773633T3 (pl) 2018-01-31
ES2645744T3 (es) 2017-12-07
LT2773633T (lt) 2017-11-10
CL2014001047A1 (es) 2014-11-07
NO2773633T3 (cg-RX-API-DMAC7.html) 2017-12-30
US20140228374A1 (en) 2014-08-14
CN106279110B (zh) 2019-12-10
CN104024244A (zh) 2014-09-03
EA201400521A1 (ru) 2014-09-30
CY1120974T1 (el) 2019-12-11
AU2012331274B2 (en) 2017-06-08
HK1196819A1 (zh) 2014-12-24
US9920035B2 (en) 2018-03-20
PE20141607A1 (es) 2014-11-23
CN104024244B (zh) 2016-09-14
CN106279110A (zh) 2017-01-04
EA025158B1 (ru) 2016-11-30
CA2854217C (en) 2019-12-31
WO2013064450A1 (en) 2013-05-10
HRP20171614T1 (hr) 2017-12-01
US8759349B2 (en) 2014-06-24

Similar Documents

Publication Publication Date Title
CO6940429A2 (es) Compuestos heterocíclicos, medicamentos que los contienen, uso de aquellos y procesos para su preparación
BR112013020362A2 (pt) processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem
CR20150380A (es) Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
BR112016000489A2 (pt) composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
CR20140259A (es) Compuestos novedosos de benzopirano, composiciones y usos de los mismos
CO6801774A2 (es) Compuestos de benzotiazol y su uso farmacéutico
BR112014029530A2 (pt) compostos, composição farmacêutica e uso de um composto
CL2014003136A1 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos; composicion farmaceutica que los contiene y usos.
BR112015000420A2 (pt) composto, composição farmacêutica, e, uso de um composto
CO6920293A2 (es) Compuestos antibaterianos y método para su uso
CO7020907A2 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmacéuticas y métodos de uso de los mismos
CL2014002093A1 (es) Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
CL2014000183A1 (es) Formulación farmacéutica que contienen anticuerpos anti-pcsk9; metodo para preparar dicha formulación.
SI3715345T1 (sl) Priprava zaviralca lfa-1
BR112015002767A2 (pt) composições, métodos, e sistemas para a síntese e uso de agentes de imagiologia
ES2603028T8 (es) Procedimiento para la preparación de (Z)-alfa-fluoro-beta-amino-acrilaldehídos sustituidos
CL2014002096A1 (es) Compuestos heterocíclicos que comprenden un sistema enediino; conjugados de los mismos; composiciones que los comprenden; y uso para tratar el cáncer
BR112012026570A2 (pt) composto, composição farmacêutica, uso de um composto, método para o tratamento de um indíviduo e produto combinado
BR112014006482A2 (pt) uso de derivados de isossorbida para produção de preparações cosméticas
CO6890098A2 (es) Compuesto pirazol y su uso farmaceutico
BR112015008908A2 (pt) uso de ivermectina e seus derivados e método para desenhar e sintetizar novos derivados
CL2014002986A1 (es) Proceso para la preparacion de compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona opticamente puros y opcionalmente sustituidos; compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona; composicion farmaceutica que los comprende; y su uso para preparar compuestos inhibidores de pi3k.
BR112013024413A2 (pt) compostos e métodos para a preparação de diarilpropanos
CO7020909A2 (es) Compuesto tricíclicos, composiciones que los comprenden y uso de los mismos